全文获取类型
收费全文 | 20458篇 |
免费 | 1497篇 |
国内免费 | 208篇 |
专业分类
耳鼻咽喉 | 161篇 |
儿科学 | 374篇 |
妇产科学 | 371篇 |
基础医学 | 2127篇 |
口腔科学 | 154篇 |
临床医学 | 3152篇 |
内科学 | 1957篇 |
皮肤病学 | 214篇 |
神经病学 | 3541篇 |
特种医学 | 244篇 |
外科学 | 1565篇 |
综合类 | 2919篇 |
现状与发展 | 1篇 |
一般理论 | 1篇 |
预防医学 | 2433篇 |
眼科学 | 106篇 |
药学 | 1536篇 |
34篇 | |
中国医学 | 828篇 |
肿瘤学 | 445篇 |
出版年
2024年 | 74篇 |
2023年 | 402篇 |
2022年 | 672篇 |
2021年 | 907篇 |
2020年 | 1003篇 |
2019年 | 836篇 |
2018年 | 738篇 |
2017年 | 802篇 |
2016年 | 807篇 |
2015年 | 752篇 |
2014年 | 1553篇 |
2013年 | 1893篇 |
2012年 | 1437篇 |
2011年 | 1479篇 |
2010年 | 1165篇 |
2009年 | 1031篇 |
2008年 | 1055篇 |
2007年 | 944篇 |
2006年 | 748篇 |
2005年 | 609篇 |
2004年 | 484篇 |
2003年 | 430篇 |
2002年 | 340篇 |
2001年 | 264篇 |
2000年 | 226篇 |
1999年 | 162篇 |
1998年 | 136篇 |
1997年 | 145篇 |
1996年 | 117篇 |
1995年 | 109篇 |
1994年 | 90篇 |
1993年 | 63篇 |
1992年 | 71篇 |
1991年 | 54篇 |
1990年 | 67篇 |
1989年 | 45篇 |
1988年 | 46篇 |
1987年 | 43篇 |
1986年 | 37篇 |
1985年 | 45篇 |
1984年 | 39篇 |
1983年 | 26篇 |
1982年 | 40篇 |
1981年 | 35篇 |
1980年 | 23篇 |
1979年 | 24篇 |
1978年 | 18篇 |
1977年 | 21篇 |
1976年 | 11篇 |
1975年 | 13篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
Simeprevir added to peginterferon and ribavirin lessens time with fatigue,depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST‐1, QUEST‐2 and PROMISE studies 下载免费PDF全文
J. Scott L. Gilles M. Fu E. Brohan C. Panter R. Arbuckle W. Jessner M. Beumont 《Journal of viral hepatitis》2015,22(8):639-650
The value of adding simeprevir (SMV) vs placebo (PBO) to peginterferon and ribavirin (PR) for treatment of chronic hepatitis C virus infection was examined using patient‐reported outcomes (PROs); further, concordance of PROs with virology endpoints and adverse events (AEs) was explored. Patients (n = 768 SMV/PR, n = 393 PBO/PR) rated fatigue (FSS), depressive symptoms (CES‐D) and functional impairment (WPAI: Hepatitis C Productivity, Daily Activity and Absenteeism) at baseline and throughout treatment in three randomised, double‐blind trials comparing the addition of SMV or PBO during initial 12 weeks of PR. PR was administered for 48 weeks (PBO group) and 24/48 weeks (SMV group) using a response‐guided therapy (RGT) approach. Mean PRO scores (except Absenteeism) worsened from baseline to Week 4 to the same extent in both groups but reverted after Week 24 for SMV/PR and only after Week 48 for PBO/PR. Accordingly, there was a significantly lower area under the curve (baseline–Week 60, AUC60) and fewer weeks with clinically important worsening of scores in the SMV/PR group at any time point. Incidences of patients with fatigue and anaemia AEs were similar in both groups, but FSS scores showed that clinically important increases in fatigue lasted a mean of 6.9 weeks longer with PBO/PR (P < 0.001). PRO score subgroup analysis indicated better outcomes for patients who met the criteria for RGT or achieved sustained virological response 12 weeks post‐treatment (SVR12); differences in mean PRO scores associated with fibrosis level were only observed with PBO/PR. Greater efficacy of SMV/PR enabled reduced treatment duration and reduced time with PR‐related AEs without adding to AE severity. 相似文献
3.
《Journal of vascular and interventional radiology : JVIR》2020,31(3):378-387
PurposeTo determine if cone-beam CT and digital subtraction angiography analysis of pelvic arterial anatomy has predictive value for radiation exposure and technical success of prostatic artery embolization (PAE).Materials and MethodsThis prospective, nonrandomized, single-center study included 104 consecutive patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia. Cone-beam CT was performed in 160/208 (76.9%) hemipelves to determine prostatic artery (PA) origin. Classification of pelvic arterial tortuosity was possible in 73/104 (70.2%) patients. Learning curves of 2 interventionalists who performed 86.5% of PAEs were analyzed.ResultsTortuosity of pelvic arteries was classified as mild in 25 (34.2%) patients median age 64 years, moderate in 40 (54.8%) patients median age 69 years, and severe in 8 (11.0%) patients median age 70 years (mild vs moderate, P = .002; mild vs severe, P = .019); median fluoroscopy times were 24, 36, and 46 minutes (P = .008, P = .023); median contrast volumes were 105, 122.5, and 142 mL (P = .029, P = .064); and bilateral PAE rates were 84.0%, 77.5%, and 62.5% (P = .437), respectively. PA origin from superior vesical artery was most frequent (27.5%) and showed higher dose area product (median 402.4 vs 218 Gy ∙ cm2, P = .033) and fluoroscopy time (median 42.5 vs 27 min, P = .01) compared with PA origin from obturator artery, which was least frequent. Interventionalist experience revealed significant impact on procedure times (median 159 vs 130 min, P = .006).ConclusionsTortuosity of pelvic arteries was more frequent in older patients and predicted worse technical outcomes of PAE. PA origin from obturator artery was associated with lower dose area product and fluoroscopy time, especially compared with PA origin from superior vesical artery. Interventionalist experience showed significant influence on technical outcome. 相似文献
4.
The present study sought to investigate the association between social phobia symptoms and self‐reported physical symptoms and the moderation effect of resting respiratory sinus arrhythmia (RSA) on this link. Data of 5‐min resting RSA, social phobia symptoms assessed by the Social Phobia Scale, and physical symptoms assessed by the Cohen–Hoberman Inventory of Physical Symptoms were collected from 167 undergraduate students. Results indicated that higher levels of social phobia symptoms were associated with higher levels of self‐reported physical symptoms. Resting RSA played the moderating role in the link between social phobia symptoms and self‐reported physical symptoms, such that social phobia symptoms were positively associated with self‐reported physical symptoms among individuals with low resting RSA, whereas this association was nonsignificant among individuals with high resting RSA. These findings suggest that high resting RSA as a physiological marker of better self‐regulation capacity might buffer the effect of social phobia symptoms on physical health. 相似文献
5.
6.
Daniel J. Ureche Jordan P. Davis Karen M. Tabb 《Journal of ethnicity in substance abuse》2016,15(2):176-188
Obtaining accurate assessment data from adolescents in treatment aids clinical decision making and facilitates more accurate outcome evaluations. However, findings could be biased due to underreported substance use and mental health symptoms. This article compares self-reports of youth in non-White matched client–assessor dyads and those in nonmatched dyads. There were no differences on self-reported substance use, but matched youth reported significantly fewer attention deficit/hyperactivity disorder symptoms versus the comparison group. One possible reason for these findings is the effect of in-group stereotype threat. Future studies should examine the potential effect that in-group stereotyping and perceived racism have on the therapeutic relationship. 相似文献
7.
目的 分析子宫腺肌症可能对患者造成的心理影响,探讨子宫腺肌症患者的心理护理方法,观察护理效果。方法 将62例子宫腺肌症患者随机分配为常规护理干预组和心理护理干预组,每组31例。对常规护理干预组患者,实施常规护理干预措施。对心理护理干预组患者,在常规护理干预措施的基础上,进一步对其实施针对性的心理护理干预措施。结果 心理护理干预组患者的焦虑自评量表(SAS)评分、抑郁自评量表(SDS)评分,以及睡眠质量自评量表(SRSS)各维度评分,都明显低于常规护理干预组,差异具有统计学意义。心理护理干预组患者的生活质量综合评定量表(GQOLI-74)各维度评分,要显著的高于常规护理干预组,差异同样具有统计学意义。结论 应重视并切实做好对子宫腺肌症患者的心理护理工作,这能够有效缓解患者的焦虑、抑郁情绪,提高患者的心理健康水平,改善患者的水平及生活质量。 相似文献
8.
9.
目的 探讨人格特征对喉鳞状细胞癌(LSCC)患者术后近期心理健康状况的影响。方法 纳入2017年1月—2019年12月在湖北省肿瘤医院行手术治疗的119例男性LSCC患者,术后5~7 d采用SCL-90、SAS、SDS自评量表评估术后心理状态,采用EPQ问卷测评患者的人格特征。多元线性逐步回归方法分析LSCC患者术后近期SAS和SDS评分的影响因素。结果 男性LSCC患者术后SCL-90、SAS、SDS得分显著高于中国常模(P≤0.05),EPQ中精神质(P)量表和神经质(N)量表得分高于中国常模(P<0.01)。男性LSCC患者术后躯体化、强迫、焦虑、抑郁、敌对、恐怖、偏执、精神病性因子得分均显著高于中国常模(P<0.05)。家庭收入、手术方式、术后近期是否行放化疗、P和N人格特征是术后SAS评分的影响因素(均P<0.01);家庭收入、手术方式、术后近期是否行放化疗和N人格特征是术后SDS评分的影响因素(P<0.01)。结论 LSCC患者术后近期存在抑郁、焦虑等心理障碍;具有P和N人格特征;家庭收入、手术方式、术后近期是否行放化疗以及P和N人格特征是影响术后SAS及SDS评分的独立危险因素。 相似文献
10.
《Australian critical care》2022,35(4):408-414
BackgroundClinically significant post-traumatic stress symptoms (PTSS) have been reported in up to a quarter of paediatric intensive care unit (PICU) survivors. Ongoing PTSS negatively impacts children's psychological development and physical recovery. However, few data regarding associations between potentially modifiable PICU treatment factors, such as analgosedatives and invasive procedures, and children's PTSS have been reported.ObjectivesWe sought to investigate the medical treatment factors associated with children's PTSS after PICU discharge.MethodsA prospective longitudinal cohort study was conducted in two Australian tertiary referral PICUs. Children aged 2-16 y admitted to the PICU between June 2008 and January 2011 for >8 h and <28 d were eligible for participation. Biometric and clinical data were obtained from medical records. Parents reported their child's PTSS using the Trauma Symptom Checklist for Young Children at 1, 3, 6, and 12 months after discharge. Logistic regression was used to assess potential associations between medical treatment and PTSS.ResultsA total of 265 children and their parents participated in the study. In the 12-month period following PICU discharge, 24% of children exhibited clinically elevated PTSS. Median risk of death (Paediatric Index of Mortality 2 [PIM2]) score was significantly higher in the PTSS group (0.31 [IQR 0.14–1.09] v 0.67 [IQR 0.20–1.18]; p = 0.014). Intubation and PICU and hospital length of stay were also significantly associated with PTSS at 1 month, as were midazolam, propofol, and morphine. After controlling for gender, reason for admission, and PIM2 score, only midazolam was significantly and independently associated with PTSS and only at 1 month (adjusted odds ration (aOR) 3.63, 95% CI 1.18, 11.12, p = 0.024). No significant relationship was observed between the use of medications and PTSS after 1 month.ConclusionsElevated PTSS were evident in one quarter (24%) of children during the 12 months after PICU discharge. One month after discharge, elevated PTSS were most likely to occur in children who had received midazolam therapy. 相似文献